Millions of people take Ozempic, Wegovy, or Rybelsus to manage diabetes or support weight loss. Most were warned about nausea and digestive side effects. Very few were told they could be at higher risk for severe vision loss.
That gap is now at the center of a growing wave of litigation. A landmark study published in JAMA Ophthalmology found that semaglutide users were more than four times as likely to develop a serious, irreversible eye condition called NAION. European regulators confirmed the potential risk in June 2025. A federal multidistrict litigation is already underway in the United States.
If you or someone close to you developed sudden vision loss after taking one of these drugs, this page explains what NAION is, what the science shows, and how an Ozempic blindness lawsuit works. Wagstaff & Cartmell is actively participating in this litigation and accepting cases nationwide.
What Is NAION?
NAION (non-arteritic anterior ischemic optic neuropathy) is a condition where reduced blood flow to the optic nerve causes nerve tissue to die. The optic nerve carries visual information from your eye to your brain. When blood supply to the front portion of that nerve is cut off, the result is sudden vision loss, typically in one eye.
There are no early warning signs. Vision loss often appears overnight or over just a few days, presenting as a dark patch, a blurred field, or a dramatic narrowing of sight. Some patients eventually develop damage in both eyes.
What makes NAION especially consequential in the context of these lawsuits is that the damage is permanent. There is no surgery to reverse it and no medication to restore what was lost. Many patients are left with lasting impairment that affects their ability to drive, work, read, and live independently.
NAION is associated with cardiovascular risk factors like high blood pressure and diabetes, the same conditions that often lead patients to semaglutide in the first place, which is part of why the connection took time to surface in the research literature.
The Research Linking Semaglutide to NAION
The scientific case became difficult to ignore in July 2024, when researchers at Mass Eye and Ear published a study in JAMA Ophthalmology comparing NAION rates across thousands of patients.
The numbers were significant. Patients prescribed semaglutide for type 2 diabetes were more than four times as likely to develop NAION compared to those taking other semaglutide medications. Among patients prescribed semaglutide for obesity, the risk was nearly eight times higher than that of comparable patients on other weight loss drugs. Researchers controlled for the pre-existing conditions that typically raise NAION risk, which made the association much harder to explain away.
Less than a year later, European regulators acted. In June 2025, the European Medicines Agency’s safety committee concluded that semaglutide more than doubles the risk of NAION and recommended that all semaglutide product information be updated to include NAION as a recognized side effect. That is a formal government body confirming the risk is real, documented, and serious.
In the United States, the FDA has received adverse event reports linking semaglutide to NAION, yet no NAION-specific warning has been added to U.S. drug labels for Ozempic, Wegovy, or Rybelsus.
Which GLP-1 Drugs Are Involved?
The current semaglutide NAION litigation centers on three brand-name drugs, all manufactured by Novo Nordisk and all built around the same active ingredient:
- Ozempic – injectable semaglutide approved for type 2 diabetes management
- Wegovy – injectable semaglutide approved for chronic weight management, at a higher dose
- Rybelsus – oral semaglutide tablet approved for type 2 diabetes
While other GLP-1 drugs exist, including tirzepatide (Mounjaro, Zepbound) and liraglutide (Victoza), the current NAION lawsuits focus specifically on semaglutide. The research to date has examined semaglutide most closely, and the litigation reflects that scientific record. If you took any of these three drugs and developed vision loss, your situation is directly relevant to the ongoing proceedings.
Why Novo Nordisk May Be Legally Responsible
At the heart of these lawsuits is a legal theory called failure to warn. Drug manufacturers are required to disclose known or reasonably knowable risks on product labels and in communications to prescribers. When that duty is breached, and patients are harmed as a result, legal liability can follow.
The argument here is straightforward. Evidence connecting semaglutide to NAION was accumulating through adverse event reports before the July 2024 JAMA study made it undeniable. Despite that, Novo Nordisk has not updated U.S. drug labels to warn about NAION, even as the EMA required labeling changes across Europe following its 2025 safety review.
Plaintiffs argue that doctors and patients who received an adequate warning might have chosen different medications, sought closer eye monitoring, or stopped the drug sooner. Because NAION is irreversible, those missed opportunities for prevention carry significant weight in calculating damages.
The NAION MDL: Where Litigation Stands
When many similar lawsuits arise from the same drug or product, federal courts can consolidate them into a multidistrict litigation, or MDL. This streamlines pretrial proceedings while preserving each plaintiff’s individual claim.
A GLP-1 NAION MDL was formally established in December 2025 in the Eastern District of Pennsylvania, before the same judge overseeing the separate GLP-1 gastroparesis MDL. More than 54 cases have already been consolidated, and new filings are being added regularly as more affected patients come forward. Wagstaff & Cartmell Attorney Sarah Ruane has been appointed by the MDL judge as one of the three Co-Lead Attorneys to lead this litigation.
MDLs typically move through consolidated discovery, selection of bellwether test cases, and eventual resolution through verdicts or settlements. This litigation is still early in that process, a meaningful detail for prospective plaintiffs, since earlier filing generally improves a claimant’s positioning. Wagstaff & Cartmell’s GLP-1 drug litigation team is actively participating in these proceedings and can explain where a new case would fit today.
Who May Qualify to File?
To have a viable Ozempic blindness lawsuit or Wegovy vision loss claim, most plaintiffs will need to meet the following criteria:
- Confirmed semaglutide use. Prescription or pharmacy records documenting use of Ozempic, Wegovy, or Rybelsus.
- An NAION diagnosis. A formal diagnosis from an ophthalmologist or neuro-ophthalmologist, reflected in your medical records.
- Qualifying symptoms. Sudden vision change in one eye, unexplained blurriness, a missing area of visual field, or permanent vision loss that developed during or after semaglutide use.
- A plausible timeline. Your vision loss appeared while taking the drug or within a reasonable window after stopping.
If you’re uncertain whether your situation qualifies, the clearest next step is a conversation with an attorney who knows this litigation. Contact Wagstaff & Cartmell for a free case evaluation to discuss your specific circumstances.
Documenting Your Eye Injury for a Legal Claim
Strong documentation is the foundation of any pharmaceutical injury case. If you’re considering filing, or want to preserve your legal options, here’s what to gather:
- Medical records. Request all records from ophthalmologists, optometrists, and neurologists who evaluated your vision loss. Look for mentions of NAION, ischemic optic neuropathy, optic nerve damage, or significant unexplained visual field loss.
- Prescription and pharmacy records. These establish when you started semaglutide, at what dose, and for how long—all critical for building a timeline connecting your drug use to your injury.
- Visual field test results. These tests map exactly where and how much vision has been lost. They are often central to proving the extent of injury in pharmaceutical litigation.
- Imaging studies. OCT (optical coherence tomography) scans can document structural damage to the optic nerve and provide objective evidence supporting your claim.
- Personal notes. A written account of when symptoms first appeared, how they progressed, and how vision loss has affected your daily life supports damage claims with context that medical records alone may not capture.
Preserve everything, even materials that seem minor. An attorney handling these cases can help identify documentation gaps and advise on next steps.
What Compensation May Be Available?
Because NAION is irreversible, compensation in these cases reflects the full, long-term impact of permanent vision loss, not just immediate medical costs.
- Medical expenses. Past diagnostic costs plus future expenses for specialist care, low-vision aids, and adaptive equipment.
- Lost income and earning capacity. Compensation for jobs you can no longer perform, reduced earning potential, or career changes forced by vision loss.
- Pain and suffering. Physical discomfort, emotional distress, and the psychological toll of permanent vision loss.
- Loss of quality of life. The inability to drive, read, pursue hobbies, or live independently, and the lasting effect on relationships and daily functioning.
- Permanent disability. For plaintiffs with severe or total vision loss, lifetime disability damages account for the ongoing consequences of an injury that will not improve over time.
The strength and value of any individual claim depends on the severity of vision loss, the plaintiff’s age and occupation, and the clarity of the connection between semaglutide use and the NAION diagnosis.
GLP-1 Naion Lawsuit FAQ
NAION is caused by blocked blood flow to the optic nerve, making it distinct from glaucoma, which involves elevated eye pressure that gradually damages the nerve, and macular degeneration, which affects the retina. NAION strikes suddenly and without pain. Unlike some retinal conditions, the optic nerve damage it causes is permanent, with no corrective surgery or restorative treatment available.
Yes. Ozempic, Wegovy, and Rybelsus all contain semaglutide as the active ingredient. The litigation covers all three drugs. The phrase “Ozempic blindness lawsuit” is widely used to describe the entire category of semaglutide NAION claims, regardless of which specific drug you took.
Filing deadlines are set by each state’s statute of limitations, typically two to three years from the date of injury or discovery of the injury. These deadlines vary by state and are strictly enforced. Contacting an attorney promptly protects your ability to file.
A diagnosis from an ophthalmologist or neuro-ophthalmologist carries significantly more legal weight than a general practitioner’s notation. If you haven’t seen a specialist, doing so is important for both your health and the strength of any legal claim you pursue.
Nothing upfront. The firm handles these cases on a contingency fee basis; there are no fees unless you recover compensation. Your initial case evaluation is free.
Most MDL cases resolve through negotiated settlements rather than individual trials. Some cases may move through bellwether trial proceedings, which help both sides gauge the strength of the evidence and typically inform broader settlement discussions.
Yes. Single-eye NAION causes real functional harm, including loss of depth perception and peripheral vision loss, and qualifies as a serious injury. Many of the claimants currently in the MDL experienced NAION in one eye.
You may still qualify. The relevant question is whether your vision loss developed during or within a reasonable period after your semaglutide use. An attorney can evaluate your specific timeline during a free case review.
Contact Wagstaff & Cartmell for a Free Case Evaluation of Your NAION Case
Wagstaff & Cartmell represents plaintiffs in some of the country’s most complex pharmaceutical and medical device cases, including mass tort and MDL proceedings. Our attorneys understand how MDL litigation is structured, how the evidence record gets built, and what it takes to move cases toward meaningful resolution.
The law firm joined the GLP-1 NAION MDL at an early stage, tracking the science, regulatory developments, and legal strategy from the start. That early involvement gives clients a foundation built on deep familiarity with the litigation, not a last-minute entry into a rapidly developing docket.
If you took Ozempic, Wegovy, or Rybelsus and experienced sudden or permanent vision loss, contact us today for a free consultation. There is no fee unless we recover for you.